Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Overview of attention for article published in Cancer Immunology, Immunotherapy, August 2012

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter: 1 X user

patent: 11 patents

Readers on

mendeley: 145 Mendeley

Summary X Patents

So far, Altmetric has seen 11 patents that reference this research output.

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Grant US-RE49353-E1

United States of America

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11491149-B2

United States of America

Combination immunotherapies for treatment of cancer

Grant US-11357795-B2

United States of America

Compositions and methods for combination therapy with dengue virus and dendritic cells

Grant US-10946080-B2

United States of America

Compositions and methods for producing dendritic cells

Grant US-10765727-B2

United States of America

Combination immunotherapies for treatment of cancer

Grant US-10675304-B2

United States of America

Compositions and methods for combination therapy with dengue virus and dendritic cells

Grant US-10357553-B2

United States of America

Humoral immune response against tumor antigens after treatment with a cancer antigen…

Grant US-10261091-B2

United States of America

Compositions and methods for combination therapy with dengue virus and dendritic cells

Grant US-10159727-B2

United States of America

Compositions and methods for combination therapy with dengue virus and dendritic cells

Grant US-9849167-B2

United States of America

Compositions and methods for combination therapy with dengue virus and dendritic cells

Grant US-9730989-B2

United States of America